<DOC>
	<DOCNO>NCT00449670</DOCNO>
	<brief_summary>The present study design ass lot-to-lot consistency immunogenicity GlaxoSmithKline Biologicals ' pandemic influenza candidate vaccine ( GSK1562902A ) adult age 18 60 year .</brief_summary>
	<brief_title>Assess Consistency Immunogenicity GlaxoSmithKline Biologicals ' Pandemic Influenza Vaccine ( GSK1562902A ) Adults</brief_title>
	<detailed_description>The protocol post updated reflect change due amendment protocol ( addition exclusion criterion ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A male female , include , 18 60 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential ; , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol follow period : Day 0 Day 51 , 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior Month 6 ; Month 6 Month 6 + 30 day ( Month 6 + 51 day control group ) . Previous vaccination pandemic candidate vaccine vaccine contain adjuvant study vaccine . Previous proven contact H5N1 wild type virus ( i.e . contact individual laboratoryconfirmed H5N1 infection , contact animal ( e.g . poultry ) die result H5N1 infection ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first administration candidate vaccine . Any confirm suspected immunosuppressive immunodeficient condition , autoimmune disease Guillain Barre Syndrome , base medical history physical examination ( laboratory testing require ) . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within 3 month precede first administration candidate vaccine study . Lactating woman . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first vaccination , plan use study period . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Vaccine</keyword>
</DOC>